Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting agent, by a protease-cleavable linker. BV has received accelerated approval from the US Food and Drug Admini...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqi, Tanya, Thomas, Sandra H, Chen, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959807/
https://www.ncbi.nlm.nih.gov/pubmed/24672256
http://dx.doi.org/10.2147/PGPM.S57700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959807/
https://www.ncbi.nlm.nih.gov/pubmed/24672256
http://dx.doi.org/10.2147/PGPM.S57700

Ejemplares similares